A man spraying paraquat, a pesticide linked to Parkinson's disease

The Tennessee paraquat lawyers at DRS Law are investigating paraquat lawsuits, following scientific evidence linking the popular pesticide to an increased risk of Parkinson’s Disease.

According to the New York Times:

The pesticide paraquat can increase the risk of Parkinson’s by 150 percent.

“The pesticide paraquat can increase the risk of Parkinson’s by 150 percent. It has been banned by 32 countries, including China, but not by the United States, where use on agricultural fields has doubled during the last decade, the authors noted. Both TCE and paraquat were banned years ago in the Netherlands, and the incidence of Parkinson’s there has since declined.”

The emerging evidence suggesting that Parkinson’s Disease may be caused by environmental factors, including pesticides like paraquat, has led to litigation.

What is paraquat?

According to Consumer Watch:

“Paraquat is an herbicide (plant killer) used to kill weeds and grasses in commercial agriculture. Growers use it on crops such as corn, soybeans, wheat, cotton, grapes and alfalfa. In 2017, growers used over 10 million pounds of paraquat, according to the U.S. Geological Survey.

Some of the largest manufacturers of paraquat products include Syngenta, Chevron Chemical Company, Drexel Chemical Company and Helm Agro. Paraquat brands in the U.S. include Gramoxone, Quick-Quat, Parazone, Cyclone, Helmquat, Bonfire Herbicide and Firestorm.”

What can Tennessee paraquat lawyers do?

Paraquat lawsuits are a kind of products liability litigation. Specifically, our Tennessee paraquat lawyers will argue:

“The makers of Paraquat (defendants) containing products were, under a duty to instruct (warn) applicators (generally farmers) of steps and precautions required to prevent human exposure to the toxic substance, in sufficient doses to cause adverse health consequences.
The manufacturers (defendants) failed to properly instruct applicators, regarding the steps and precautions required to prevent exposure to the toxic substance in sufficient dosages to cause the adverse health consequences the substance is known to cause.
Additionally, the manufacturers failed to instruct applicators steps and precautions required to prevent chemical trespass from overspray and chemical drift. The defendants failed to fulfill their duties.”

I’ve been exposed to paraquat and injured–what should I do?

Contact the Tennessee paraquat lawyers at David Randolph Smith & Associates right away.

We’ll hear the facts of your case and offer expert advice on what steps to take next,  and how to navigate your claim.  We have significant experience handling defective medical device lawsuits in Nashville and around the region.  We have performed extensive research on the origins and mechanism of paraquat injuries, including the link to Parkinson’s Disease. Contact us today.

Paraquat Lawsuit Updates: Recent Developments in the Paraquat Class Action Litigation

Stay Informed About the Latest Paraquat Lawsuit News and Updates


Discover the most recent updates regarding the ongoing Paraquat lawsuit, a prominent class action litigation involving individuals affected by Parkinson’s disease due to exposure to the herbicide Paraquat. In this article, we provide a comprehensive overview of the latest developments, key milestones, and critical insights related to the Paraquat class action lawsuit.

January 17, 2023 Update

In the latest update, only 69 new cases have been added to the Paraquat class action MDL over the past month, contributing to a current total of 2,352 cases. This notable decrease comes after the Paraquat MDL saw an average of over 200 new cases per month last year. The MDL docket indicates a significant rise in new member cases opened over the last 30 days, suggesting a potentially high number of new cases in the upcoming monthly total.

For plaintiffs, a relatively smaller Paraquat litigation size is advantageous. This smaller scale allows for potentially higher settlement amounts, as the defendants’ ability to manage payments is more feasible than in larger cases. The Paraquat litigation’s compact nature provides an opportunity for plaintiffs to receive quicker and more substantial payouts.

January 2, 2023 Update

As we transition into 2023, questions arise about the pace of the Paraquat class action lawsuit. Over the last two weeks alone, more than 150 new Paraquat Parkinson’s disease lawsuits have been filed in the MDL. While this rapid influx continues, expectations lean towards a slowdown in 2023, particularly as attention shifts to the initial trial and the potential for a global Paraquat settlement.

December 23, 2022 Update

The first Paraquat bellwether test trial in the federal MDL faces further postponement. The trial’s opening, initially set for November 2022, has been rescheduled to October 2023. Unexpected circumstances and delayed expert witness depositions have contributed to this delay, prompting anticipation for the forthcoming trial.

December 17, 2022 Update

Throughout 2022, the Paraquat class action MDL has experienced explosive growth. From a modest beginning of 482 Paraquat Parkinson’s disease lawsuits in early 2022, the MDL now encompasses 2,352 pending cases as of December 15, 2022. This year’s 390% increase in case count points to a substantial expansion. With indications of further case additions, the momentum shows no immediate signs of slowing down.

November 1, 2022 Update

The journey toward bellwether trials in the Paraquat Parkinson’s disease lawsuits has seen a consistent influx of new cases. Over the past six months, nearly 100 new lawsuits have entered the MDL, with the recent two weeks contributing significantly. Pretrial discovery disputes persist as both sides react to the Special Master’s report and recommendations, shaping the legal landscape as the trials draw closer.

October 1, 2022 Update

In August 2021, the EPA granted interim approval for Paraquat’s continued availability, sparking legal challenges. A non-profit foundation filed a lawsuit questioning the validity of the EPA’s decision, leading to requests for voluntary remand. This development adds complexity to the Paraquat landscape, prompting a fresh examination of the risk-benefit analysis underlying the agency’s interim approval.

September 15, 2022 Update

Despite being a relatively small class action lawsuit, the Paraquat litigation has experienced notable growth. In the last 30 days, the MDL has welcomed 222 new Paraquat Parkinson’s disease lawsuits, raising the docket total to 1,925. A dozen cases were remanded back to state court during this period, highlighting the diverse origins of new cases entering the MDL. The streamlined filing process for plaintiffs from across the country has contributed to this expansion.

September 1, 2022 Update

The Paraquat MDL Judge’s selection of 20 additional cases for limited fact discovery marks a pivotal phase in the litigation. With depositions and reports on plaintiffs’ testimonies scheduled, the legal landscape gains further clarity. The influx of around 200 new Paraquat plaintiffs over the past two weeks continues to shape the overall case dynamics, emphasizing the importance of thorough discovery.

h2>August 29, 2022 Update

Regrettably, the first bellwether test trial in the Paraquat class action MDL, initially set for November 2022, has been postponed. Judge Nancy Rosenstengel issued a Case Management Order (CMO No.15) rescheduling the trial for July 2023. This postponement allows for additional discovery time, potentially impacting the leverage for favorable settlements. Despite setbacks, the increasing viability of Paraquat lawsuits remains a positive factor.

August 15, 2022 Update

In July, the Paraquat MDL witnessed a surge of 255 new cases, setting a new record for monthly case additions. This escalation emphasizes the growing momentum of the Paraquat Parkinson’s class action lawsuit. The MDL’s total case count now stands at 1,703, reflecting sustained interest and participation from plaintiffs seeking justice.

August 1, 2022 Update

The federal Paraquat lawsuit maintains its position as a prominent mass tort class action MDL. The months leading up to August have seen consistent growth in case filings, with 142 new Paraquat lawsuits entering the MDL between May 16 and June 15. The influx continues, with an additional 54 lawsuits filed within the past 12 days. This sustained momentum underscores the significance of the Paraquat litigation.

June 10, 2022 Update

The Paraquat class action lawsuit advances with determination. The judge overseeing the proceedings has issued an extended discovery schedule, aligning deadlines to ensure the timely progress of bellwether trials this fall. The increased timeline for fact discovery and medical examinations serves to support the integrity of the trial process while maintaining the schedule for bellwether trials.

May 16, 2022 Update

With the Paraquat lawsuit’s momentum showing no signs of abating, the MDL has seen a substantial increase of 57 new Paraquat Parkinson’s disease lawsuits filed or transferred into the MDL within the first week of May 2022. The second week of May contributed another 35 new cases, highlighting the growing volume of filings in this pivotal litigation.

May 11, 2022 Update

Bayer’s recent setback in Roundup cases has implications for the Paraquat lawsuit as well. The Biden administration’s stance against preemption arguments reinforces the position that approval of labeling not warning about chronic risks does not preempt state-law requirements. This development weakens certain defenses and sets a precedent that could impact the Paraquat litigation’s direction and outcomes.

May 6, 2022 Update

Efforts to secure a Paraquat trial date remain critical for achieving favorable settlements. While the trial date has seen postponements, the judge’s suspension of certain deadlines highlights the need for efficient case preparation. The push to streamline fact discovery and medical examinations serves as a cornerstone for progressing toward a November 15, 2022 trial.

May 2, 2022 Update

Continuing the trend of active developments, the MDL judge has finalized a group of six Paraquat lawsuits for the upcoming bellwether trials set to commence in the fall. The selection process involved input from both plaintiffs’ and defense attorneys, resulting in the identification of these six cases. Fact and expert discovery are underway as both sides prepare for these pivotal bellwether trials.

April 14, 2022 Update

Recent weeks have seen a notable increase in the influx of Paraquat lawsuits, with 44 new cases transferred into the MDL. This surge indicates a potential record-setting month for new filings. In parallel, the selection of class action bellwether cases is in progress, with choices yet to be publicly disclosed, setting the stage for significant developments in the Paraquat litigation.

April 1, 2022 Update

The monthly status conference on April 1, 2022, will provide critical insights into the current state of the Paraquat MDL. Judge Nancy Rosenstengel will share updates on the litigation’s size, including a summary of new case additions. Additionally, the discussion will revolve around the selection process for upcoming bellwether trials, shedding light on the next phase of the Paraquat class action lawsuit.

March 21, 2022 Update

With the Paraquat Parkinson’s disease class action steadily progressing, a group of 16 cases has been earmarked for the initial round of bellwether trials, slated to begin in the upcoming fall. Divided equally between plaintiffs’ and defense selections, these cases will undergo rigorous fact discovery to establish their eligibility for the bellwether trials. The forthcoming weeks will see intense preparations on both sides.

March 16, 2022 Update

The Paraquat MDL continues to gain traction, with the total number of lawsuits reaching 875. While this figure is lower than some other mass tort litigations, it bears significance due to potentially higher settlement amounts for plaintiffs. The smaller volume of victims allows for more manageable individual settlement compensation payouts, ensuring that defendants can meet their obligations.

March 3, 2022 Update

A recent ruling by the judge in the Paraquat class action lawsuits addresses several motions to dismiss filed by the defendants. While some claims were dismissed, the majority remain valid and will proceed. This verdict paves the way for the first round of bellwether trials scheduled for 10 months from now, reinforcing the possibility of reasonable settlements for Parkinson’s disease victims before the trial begins.

February 10, 2022 Update

Despite facing challenges, the Paraquat class action lawsuit continues to make strides. A recent development saw plaintiffs’ attorneys secure a minor discovery victory, obtaining access to deposition transcripts from Syngenta corporate witnesses. This development carries significance, given the potential insights that could emerge from these transcripts, contributing to a more comprehensive understanding of the case.

February 4, 2022 Update

The momentum of the Paraquat lawsuit remains unwavering, as over a dozen new cases were filed in a single day. Plaintiffs, whose lives have been impacted by Parkinson’s disease due to Paraquat exposure, continue to seek justice. With defendants settling some cases confidentially, the spotlight shifts to potential high settlement amounts and the ongoing effort to bring these cases to light.

February 1, 2022 Update

Preparations for the bellwether test trials are gaining momentum, as a selection of 16 cases has been identified for this pivotal phase. The participation of both plaintiffs’ and defense lawyers in choosing these cases underscores their significance. As fact discovery progresses, the groundwork is being laid for a meaningful set of trials that will shape the future of the Paraquat class action lawsuit.


These updates provide valuable insights into the dynamic landscape of the Paraquat class action lawsuit. The evolving situation, with its trials, settlements, and developments, underscores the significance of staying informed and up-to-date on the progress of this pivotal legal case.

For more in-depth information and the latest updates, please continue to follow our coverage of the Paraquat lawsuit.

[dsm_icon_list _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}” theme_builder_area=”post_content”][/dsm_icon_list]